var data={"title":"Agalsidase alfa: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Agalsidase alfa: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/324849?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=agalsidase-alfa-patient-drug-information\" class=\"drug drug_patient\">see &quot;Agalsidase alfa: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50768559\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Replagal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4803327\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Enzyme</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4803359\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premedication with oral antihistamines and corticosteroids may alleviate infusion-related reactions associated with agalsidase alfa.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fabry disease:</b> IV: 0.2 mg/kg every 2 weeks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991980\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50989162\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; has not been studied</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4803358\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premedication with oral antihistamines and corticosteroids may alleviate infusion-related reactions associated with agalsidase alfa.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fabry disease:</b> Children &ge;7 years and Adolescents: IV: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4803360\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">No data available. Safety and efficacy have not been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50756657\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, Intravenous [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Replagal: 1 mg/mL (3.5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11216688\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4803363\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Must be diluted further prior to infusion; do not administer undiluted. Infuse IV over 40 minutes using a dedicated IV line with filter. Do not infuse other agents through same IV line. Interrupt infusion in the presence of infusion-related reactions; infusion may be restarted after 5 to 10 minutes if symptoms are mild and subside.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4803329\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fabry disease:</b> Enzyme replacement therapy for Fabry disease (alpha-galactosidase A deficiency)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4803319\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Agalsidase alfa may be confused with agalsidase beta, alglucosidase alfa.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4803336\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (9% to 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Infusion related reaction (14%; more common in children &amp; adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain, chest tightness, flushing, hypertension, livedo reticularis, oxygen saturation decreased, palpitations, peripheral edema, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Altered sense of smell, dizziness, fatigue (including fatigue aggravated), feeling hot, feeling of heaviness, headache, hypersomnia, hypoesthesia, local discomfort, malaise, neuralgia, pain, paresthesia, rigors, sensation of cold</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Acne vulgaris, erythema, hyperhidrosis, pruritus, rash at injection site, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distress, abdominal pain, diarrhea, dysgeusia, nausea, nausea and vomiting, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylaxis, angioedema (with stridor, swollen tongue, throat tightness), hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, joint swelling, limb pain, musculoskeletal pain (discomfort), myalgia, swelling of extremities, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Increased lacrimation, reduced blinking</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Tinnitus (including tinnitus aggravated)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough, dyspnea, flu-like symptoms, hoarseness, increased bronchial secretions, nasopharyngitis, pharyngeal edema, pharyngitis, rhinorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Severe infusion related reaction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4803332\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Severe hypersensitivity to agalsidase alfa or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4803333\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: Patients may develop antibodies to agalsidase alfa. The presence of antibodies has been observed following approximately 6 to 12 months of therapy. In some clinical trials, the persistence of antibodies has been observed in up to 17% of patients after 12 to 54 months of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis, have been reported with agalsidase alfa use. Discontinue therapy immediately for hypersensitivity reaction and treat appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Mild acute reactions (eg, headache, nausea, flushing, fatigue) are common while severe reactions (angioedema, nausea/vomiting, pyrexia, rigors, tachycardia, urticaria) are rare. Reactions have generally occurred within 2 to 4 months after therapy initiation although a later onset (ie, after 1 year) has also been observed. Reactions may decrease over time. If a mild or moderate acute infusion reaction occurs, the infusion may be temporarily interrupted (5 to 10 minutes) until the acute reaction subsides. Patients with a history of reactions may be premedicated with oral corticosteroids and antihistamines 1 to 24 hours prior to subsequent infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Impaired renal function (eGFR &lt;60 mL/minute) may limit the renal response to enzyme replacement therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298691\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4803343\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8515&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May diminish the therapeutic effect of Agalsidase Alfa.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroquine: May diminish the therapeutic effect of Agalsidase Alfa.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gentamicin (Systemic): May diminish the therapeutic effect of Agalsidase Alfa.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4803330\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Information related to use in pregnancy is limited (Kalkum 2009; Senocak Tasci 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21096298\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if agalsidase alfa is excreted into breast milk. The manufacturer recommends using with caution in breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4803350\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Agalsidase alfa is a recombinant form of the enzyme alpha-galactosidase-A, which catalyzes the hydrolysis of globotriaosylceramide (Gb-3), cleaving a terminal galactose residue from the molecule. Accumulation of globotriaosylceramide (Gb-3) may occur within the tissues of patients with Fabry disease. Agalsidase has been noted to reduce cellular levels of Gb-3 in many cell types including endothelial and parenchymal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4803352\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: In a study of 17 adult males, median V<sub>d</sub> was 203 mL/kg (range: 89 to 6,778 mL/kg); in 14 pediatric patients, mean V<sub>d</sub> was 128 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Plasma; via peptide hydrolysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: In a study of 17 adult males, median half-life was 54.7 minutes (range: 28.5 to 654.2 minutes); in 14 pediatric patients, mean half-life was 32 minutes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50781770\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Nogasin GO (SG);</li>\n      <li>Replagal (AT, AU, BE, CH, CO, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IL, IS, IT, JP, KR, LT, LU, LV, MT, NL, NO, NZ, PL, PT, PY, RO, RU, SE, SI, SK, TR, TW, ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Kalkum G, Macchiella D, Reinke J, et al. Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease. <i>Eur J Obstet Gynecol Reprod Biol.</i> 2009;144(1):92-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/agalsidase-alfa-drug-information/abstract-text/19233535/pubmed\" target=\"_blank\" id=\"19233535\">19233535</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Replagal (agalsidase alfa) [Canadian product monograph]. Lexington, MA: Shire Human Genetic Therapies Inc; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Senocak Tasci E, Bicik Z. Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease. <i>Iran J Kidney Dis</i>. 2015;9(5):406-408.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/agalsidase-alfa-drug-information/abstract-text/26338166./pubmed\" target=\"_blank\" id=\"26338166.\">26338166.</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8515 Version 83.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50768559\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F4803327\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F4803359\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991980\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50989162\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F4803358\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F4803360\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F50756657\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11216688\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F4803363\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F4803329\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F4803319\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F4803336\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F4803332\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F4803333\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298691\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F4803343\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4803330\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21096298\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F4803350\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F4803352\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F50781770\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8515|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=agalsidase-alfa-patient-drug-information\" class=\"drug drug_patient\">Agalsidase alfa: Patient drug information</a></li></ul></div></div>","javascript":null}